Investigational drug · Phase 2
BNT116
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Non-Small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: May 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "BNT116"
First trial start
2023
Apr 21, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BNT116", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Non-Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BNT116" as an intervention, largest first.
BioNTech SEIndustry
NCT05142189 · 320 participants (planned) · Start Jun 17, 2022 · Primary completion Feb 2030
Drug: BNT116; Cemiplimab and 9 more · For: Non-Small Cell Lung Cancer
Sites: Lexington, Kentucky; Louisville, Kentucky; Baltimore, Maryland · 45 sites in all
- A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)Active, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05557591 · 51 participants · Start Apr 21, 2023 · Primary completion Jan 26, 2028
Drug: BNT116; Cemiplimab · For: Advanced Non-Small Cell Lung Cancer
Sites: Los Angeles, California; Santa Monica, California; Louisville, Kentucky · 52 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The advantages of NK cell vaccines in solid carcinoma clinical trials: conducted by various biology strategy and technology.
Hu Y, Leng L, Li B, et al. · Front Med (Lausanne) 2025
- Shared epitopes create safety and efficacy concerns in several cancer vaccines.
Kellermann G, Mograbi B, Hofman P, et al. · J Immunother Cancer 2025
- Groundbreaking mRNA Lung Cancer Vaccine Trials: A New Dawn in Cancer Treatment.
Hussain MS, Sultana A, Bisht AS, et al. · Curr Cancer Drug Targets 2025
Also in development for Advanced Non-Small Cell Lung Cancer
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- FurmonertinibPhase 38 trials
Allist Pharmaceuticals, Inc. · Non-Small Cell Lung Cancer, NSCLC, NSCLC Patients With Brain Metastasis
- JSKN016Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Triple Negative Breast Cancer, Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer
- QuemliclustatPhase 33 trials
Arcus Biosciences, Inc. · Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Non-Small Cell Lung Cancer, Gastrointestinal Tract Malignancies
- KN046Recombinant Humanized PD-L1, CTLA-4 Bispecific Single Domain Antibody Fc Fusion ProteinPhase 22 trials
InxMed (Shanghai) Co., Ltd. · Pancreatic Cancer, Advanced Non-small Cell Lung Cancer
- QuavonlimabMK-1308Phase 22 trials
Merck & Co. · Melanoma, Advanced Non-Small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.